Jade Biosciences, Inc. (JBIO)
| Market Cap | 229.97M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -93.96M |
| Shares Out | 31.42M |
| EPS (ttm) | -18.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 226,025 |
| Open | 7.59 |
| Previous Close | 7.49 |
| Day's Range | 6.98 - 7.62 |
| 52-Week Range | 1.25 - 25.29 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 17.00 (+132.24%) |
| Earnings Date | May 14, 2025 |
About JBIO
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company was incorporated in 2024 and is headquartered in Waltham, Massachusetts. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for JBIO stock is "Buy" and the 12-month stock price forecast is $17.0.
News
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to ent...
Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference
SAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies f...